Methylation and Immunoexpression of p16INK4a Tumor Suppressor Gene in Primary Breast Cancer Tissue and Their Quantitative p16INK4a Hypermethylation in Plasma by Real-Time PCR
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The p16INK4a gene methylation has been reported to be a major tumorigenic mechanism. Methods: We evaluated the methylation status of the p16INK4a genes in 231 invasive breast cancer and 90 intraductal carcinoma specimens using a methylation-specific polymerase chain reaction and p16 protein expression using immunohistochemistry. The quantity of cell-free methylated p16INK4a DNA in the plasma samples of 200 patients with invasive breast cancer was also examined using a fluorescence-based real-time polymerase chain reaction assay. Results: The frequencies of p16INK4a methylation in invasive and intraductal tumors were 52.8% (122/231) and 57.8% (52/90),respectively. The p16 protein was overexpressed in 145 of the 231 invasive carcinomas (62.8%) and 63 of the 90 intraductal carcinomas (70%). High p16 expression in invasive carcinomas correlated significantly with a high histologic grade, a negative estrogen receptor and progesterone receptor status, p53 immunoreactivity and high Ki-67 expression with immunohistochemistry. In addition, the methylation index of p16INK4a was significantly higher in the cancer patients than the normal controls (p<0.001). Conclusions: High p16 immunoreactivity correlated with a loss of differentiation in breast carcinomas and high frequency of p16INK4a promoter methylation in both invasive and intraductal carcinomas, suggesting it maybe involved in the pathogenesis of breast cancer.
Abstract
Background: The p16INK4a gene methylation has been reported to be a major tumorigenic mechanism. Methods: We evaluated the methylation status of the p16INK4a genes in 231 invasive breast cancer and 90 intraductal carcinoma specimens using a methylation-specific polymerase chain reaction and p16 protein expression using immunohistochemistry. The quantity of cell-free methylated p16INK4a DNA in the plasma samples of 200 patients with invasive breast cancer was also examined using a fluorescence-based real-time polymerase chain reaction assay. Results: The frequencies of p16INK4a methylation in invasive and intraductal tumors were 52.8% (122/231) and 57.8% (52/90),respectively. The p16 protein was overexpressed in 145 of the 231 invasive carcinomas (62.8%) and 63 of the 90 intraductal carcinomas (70%). High p16 expression in invasive carcinomas correlated significantly with a high histologic grade, a negative estrogen receptor and progesterone receptor status, p53 immunoreactivity and high Ki-67 expression with immunohistochemistry. In addition, the methylation index of p16INK4a was significantly higher in the cancer patients than the normal controls (p<0.001). Conclusions: High p16 immunoreactivity correlated with a loss of differentiation in breast carcinomas and high frequency of p16INK4a promoter methylation in both invasive and intraductal carcinomas, suggesting it maybe involved in the pathogenesis of breast cancer.
참고문헌 (30)
- Kamb A, "A cell cycle regulator potentially involved in genesis of many tumor types", Science, 264, pp.436~440 (1994)
- Serrano M, "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D", CDK4, 1993, pp.366, 704~707
- Herman JG, "Inactivation of the CDKN2", p16, Cancer Res, pp.1995, 55[DOI]
- Di Vinci A, "p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma", Int J Cancer, 114, pp.414~421 (2005)
- Emig R, "Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation", Br J Cancer, 78, pp.1661~1668 (1998)
- Han S, "P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy", Breast Cancer Res Treat, 70, pp.205~212 (2001)
- Milde-Langosch K, "Expression of cell cycle-regulatory proteins rb, p16", MTS1, p27, WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members, pp.Int J Cancer, 2000[DOI]
- Kersting M, "Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers", J Clin Oncol, 18, pp.3221~3229 (2000)
- Kresty LA, "Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia", Cancer Res, 62, pp.5295~5300 (2002)
- Lee JH, "Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas", ONCOGENE, 23(26), pp.4646~4654, NATURE PUBLISHING GROUP
- Bearzatto A, "p16(INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer", Clin Cancer Res, 8, pp.3782~3787 (2002)
- Hsiung DT, "Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma", Cancer Epidemiol Biomarkers Prev, 16, pp.108~114 (2007)
- Kawakami K, "Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma", J Natl Cancer Inst, 92, pp.1805~1811 (2000)
- Lee TL, "Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma", Clin Cancer Res, 8, pp.1761~1766 (2002)
- Sharma G, "Promoter hypermethylation of p16INK4A, p14ARF, cyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients", Life Sci, 80, pp.1873~1881 (2007)
- Zhang YJ, "Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA", Clin Cancer Res, 13, pp.2378~2384 (2007)
- Zitt M, "DNA methylation in colorectal cancer: impact on screening and therapy monitoring modalities?", Dis Markers, 23, pp.51~71 (2007)
- Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod Pathol, 11, pp.155~168 (1998)
- Fackler MJ, "Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer", Cancer Res, 64, pp.4442~4452 (2004)
- Brenner AJ, "Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer", Clin Cancer Res, 2, pp.1993~1998 (1996)
- Hui R, "INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis", Clin Cancer Res, 6, pp.2777~2787 (2000)
- Nielsen NH, "Methylation of the p16(Ink4a) tumor suppressor gene 5’-CpG island in breast cancer", Cancer Lett, 163, pp.59~69 (2001)
- Liu T, "Methylation of CpG islands of p16(INK4a) and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breast", Hum Pathol, 39, pp.1637~1646 (2008)
- Bachmann IM, "Altered expression of cell cycle regulators cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas", Int J Oncol, 25, pp.1559~1565 (2004)
- Khouja MH, "The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma", Int J Gynecol Pathol, 26, pp.418~425 (2007)
- Saegusa M, "Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1", CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas, 2001, pp.92, 1177~1189
- Geradts J, "Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2", MTS1 gene. A comparison of four commercial antibodies, 2000, pp.8, 71~79
- Dublin EA, "Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters", Int J Cancer, 79, pp.71~75 (1998)
- Geradts J, "High frequency of aberrant p16(INK4A) expression in human breast cancer", Am J Pathol, 149, pp.15~20 (1996)
- Leong WF, "p53 Deficiency leads to compensatory up-regulation of p16INK4a", Mol Cancer Res, 7, pp.354~360 (2009)